Novo Nordisk's Buyback Engine Keeps Running as Rebrand and Strategy Day Loom

Novo Nordisk has repurchased 33.08M B-shares for about 9.3B kroner, with a rebrand to "Novo" and a London capital markets day set for 21 September.

Novo Nordisk has quietly amassed a substantial stake in itself. According to company disclosures, the Danish drugmaker had repurchased 33,084,179 B-shares as of 11 September at an average price of 281.89 Danish kroner apiece, translating into a transaction value of roughly 9.33 billion kroner. That figure has since been rounded to about 9.3 billion kroner in the company's own communications.

The buyback activity represents steady progress from just a week earlier. As of 4 September, Novo Nordisk held 32,034,179 B-shares bought back at an average of 281.63 kroner. All told, the group now counts 47,124,876 B-shares as treasury stock — equivalent to 1.1 percent of its share capital.

The repurchase effort sits within a broader framework. The overarching programme, worth 15 billion kroner, was launched on 4 February and spans twelve months. A separate tranche of up to 11.2 billion kroner runs until 1 February 2027. Management's willingness to commit such sums suggests confidence in the balance sheet and a belief that the stock is undervalued at current levels.

A Stock Still Searching for a Floor

That conviction is being tested by the market. The shares last changed hands at EUR 36.73, roughly 33 percent below the 52-week high of EUR 54.86 touched in late January. Since the turn of the year, the equity has shed 16 percent of its value. Buybacks may underpin demand, but they have yet to reverse the broader downtrend.

The pressure intensified after Morgan Stanley downgraded the stock last Friday, an event whose ripple effects are still being felt. The bank's central concern: semaglutide, the active ingredient behind Wegovy and Ozempic, accounts for an estimated 75 percent of this year's revenue — and its patent protection lapses in 2031. How Novo Nordisk intends to fill that gap is now the question dominating investor conversations.

Clinical Wins Offer a Counterweight

Not all recent news has been discouraging. On 7 September, the company reported positive Phase 3 data from the STEP Young trial. Among children aged six to under twelve who received weekly semaglutide, 40.4 percent were no longer classified as obese after 68 weeks, compared with zero percent in the placebo arm. No new safety signals emerged regarding growth or pubertal development. Full results are slated for presentation at ObesityWeek in Washington this November.

Such findings could eventually open the door to new patient populations, widening the growth base beyond established indications. For now, they serve as a reminder that Novo Nordisk's pipeline extends past the semaglutide franchise.

Rebranding and a London Reckoning

Alongside the clinical and capital-return activity, the company is preparing a deeper transformation. On 14 September, Novo Nordisk announced it will henceforth trade under the shortened name "Novo," accompanied by the tagline "Lasting Health Starts Now" and a revised cultural framework dubbed "The Novo Way." The legal entity Novo Nordisk A/S remains unchanged, and the Apis bull logo is being modernised rather than replaced. The move is designed to sharpen recognition in the core diabetes and obesity markets.

The full strategic picture will be laid out at a capital markets day in London on 21 September. That event now carries outsized significance. Investors want specifics on how management plans to secure medium-term growth once semaglutide's exclusivity expires, and whether the rebranding amounts to more than a cosmetic shift.

Between the buyback programme, the paediatric data, and the rebrand, Novo Nordisk is plainly trying to steer the narrative away from pure price debate and toward substance. Whether that effort succeeds may become clearer in London — when the company's long-term direction is finally put on the table.